Sun Pharmaceutical Industries Limited /
Concert Pharmaceuticals, Inc.
Sun Pharma completes acquisition of Concert Pharmaceuticals
- Price per share
- $8.00/share
- Stage
- Closed
What happened
Sun Pharmaceutical Industries Limited completed its acquisition of Concert Pharmaceuticals, Inc. on March 6, 2023. Concert is a late-stage clinical biopharmaceutical company developing deuruxolitinib for the potential treatment of alopecia areata.
The offer included $8.00 per share in cash and a contingent value right with potential payments of up to $3.50 per share.
The source
Everything on this page comes from the source below.
Sun Pharma completes acquisition of Concert Pharmaceuticals
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly